Human Primary Dermal Microvascular Endothelial Cells

Description

Human Primary Dermal Microvascular Endothelial Cells from Cell Biologics are isolated from human skin tissue and grown in gelatin pre-coated tissue culture flask with Cell Biologics’ Complete Growth Medium. Cells at passage 3 are harvested from flasks and cryo-preserved in vials. Each vial contains 0.5x106 cells per ml and is delivered frozen. Human Primary Dermal Microvascular Endothelial Cells are characterized by immunofluorescence staining with antibodies of CD31 (Catalog No. 550389, BD), CD31/PECAM-1 (Catalog No. FAB3567P, R&D), VE-Cadherin (FITC-VE-cadherin, Catalog No. 560411, BD), or use of fluorescence-labeled acetylated low-density lipoprotein (DiI-Ac-LDL) uptake (Catalog No. L-35353, Invitrogen), a functional marker for endothelial cells. These cells are negative for bacteria, yeast, fungi, and mycoplasma and can be expanded for 3-5 passages at a split ratio of 1:2 under the cell culture conditions specified by Cell Biologics. Repeated freezing and thawing of cells are not recommended. Human Primary Dermal Microvascular Endothelial Cells can be used for cell-based adhesion, migration, vascular tube formation, transendothelial resistance (TER), western blot, immunoprecipitation, immunofluorescence flow cytometry, polymerase chain reaction, and generating cell derivatives for desired research applications.

Suggested Medium

H1168 Complete Human Endothelial Cell Medium w/ Kit – 500 ml

Storage

Cryopreserved cells are shipped with dry ice overnight. Upon arrival, transfer frozen cells to liquid nitrogen (-180°C) immediately until ready for use. Live cell shipment is also available on request. Primary cells can never be kept at -20 °C or -80 °C freezer.

Documents

Primary Endothelial Cell Culture Protocol

MSDS.CellBiologics

H-6064

Disclaimer

Investigators should handle the cells with caution and treat all primary cells as potential pathogens, since no test procedure can completely guarantee the absence of infectious agents. 

Publication

Br J Pharmacol. 2012 Jan; 165(1): 208–222.